Project Grant R41DA062978
Award Date
5/1/25
Completion Date
4/30/26
Dollars Obligated
$399K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression during chronic opioid exposure, and biophysically characterize their drug-protein interactions. The efficacy...
This $397,829 Project Grant was awarded on May 1, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Callentis Consulting Group LLC, a woman-owned small business. The grant supports the development of an AI-based platform to identify and validate potential drug targets and compounds for treating substance use disorders. The key products and services to be delivered include: Curated training datasets and machine learning...
This $716,226 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel small molecule allosteric modulators targeting the neurotensin receptor 1 (NTSR1) as a potential treatment for opioid use disorder (OUD). The overarching goals are to: 1) validate NTSR1 as a viable drug target for treating OUD, and 2) discover next-generation NTSR1 modulators with improved selectivity for...
This Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to identify therapeutic molecules that can bind to the GPR26 receptor and potentially treat opioid use disorders without directly targeting opioid receptors. The $399,884 Phase I SBIR project will utilize DNA-encoded library (DEL) technology to screen 125 million compounds and identify 100 preferred hits. The awardee, Jillion Therapeutics Inc., will...
This $858,600 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh. The grant aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex that could be targeted for developing new treatments for opioid use disorder (OUD). The research will use an unbiased transcriptomics approach to identify...
This federal Project Grant award of $275,253 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports Epivario Inc.'s research to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The key products and services being delivered through this grant include: Epivario is screening next-generation inhibitors of the metabolic enzyme ACSS2, which has been shown to play a role in the encoding of...
This $751,043 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research investigating the cellular and molecular mechanisms underlying the complex co-occurrence of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The award will fund a comprehensive study using advanced multi-omics approaches, including single-nucleus RNA sequencing and single-nucleus ATAC...
This $399,536 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to design, synthesize, and test non-opioid drug candidates that can help combat the national opioid crisis, with a focus on reversing the effects of synthetic opioids like fentanyl. The key goals are to: 1) Develop and characterize chemical lead compounds and control...
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Tenvos Inc., a minority-owned and woman-owned technology company. The grant will support the development of a software-based medical device (SAMD) integrated into a smartphone application that can detect opioid use through voice analysis. The proposed solution aims to enable patients in outpatient opioid use disorder (OUD) treatment to remotely test for...
This $810,668 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on evaluating an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to demonstrate the feasibility of DRHQ, which is moving from the lead optimization stage into preclinical development. The research will be conducted by Virogenomics...